Abdi Rasekh is a Cardiology physician affiliated with Houston Methodist. OpenAlex indexes 114 publications with 2,439 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6624 Fannin
#2480
Houston, TX 770302309
Telephone
713-529-5530Provider last certified this registry record 17 Oct 2023.
Clinical trials
- NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
Sponsor: Biosense Webster, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year202545 payments
- Boston Scientific CorporationProgram year202520 payments
- Biosense Webster, Inc.Program year202521 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
74.8%Beta blocker21.5%Metoprolol Succinate64%Metoprolol Tartrate15%Carvedilol13%Sotalol8%Part D<11 patientsAntiarrhythmic16.9%Amiodarone Hcl64%Flecainide Acetate36%Part D≥36 patients+ 7 more classes in this area
Blood & clotting
23.5%Factor Xa inhibitor19.3%Eliquis83%Xarelto17%Part D≥49 patientsP2Y12 inhibitor2.6%Clopidogrel100%Part D≥11 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.7%Potassium supplement1.7%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Mortality in Recipients of Durable Left Ventricular Assist Devices Undergoing Ventricular Tachycardia Ablation
JACC. Clinical electrophysiology
2024 - Incidence, Risk Score Performance, and In-Hospital Outcomes of Postoperative Atrial Fibrillation After Cardiac Surgery
Texas Heart Institute Journal
2023 - Slow‐pathway visualization by using voltage‐time relationship: A novel technique for identification and fluoroless ablation of atrioventricular nodal reentrant tachycardia
Journal of Cardiovascular Electrophysiology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Bita Esmaeli, MD
Houston Methodist
Sherif Nagueh, MD
Houston Methodist
Neal Kleiman, MD
Houston Methodist
Miguel Quinones, MD
Houston Methodist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”